These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Campochiaro PA; Heier JS; Feiner L; Gray S; Saroj N; Rundle AC; Murahashi WY; Rubio RG; Ophthalmology; 2010 Jun; 117(6):1102-1112.e1. PubMed ID: 20398941 [TBL] [Abstract][Full Text] [Related]
4. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Chun DW; Heier JS; Topping TM; Duker JS; Bankert JM Ophthalmology; 2006 Oct; 113(10):1706-12. PubMed ID: 17011952 [TBL] [Abstract][Full Text] [Related]
5. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. Pieramici DJ; Rabena M; Castellarin AA; Nasir M; See R; Norton T; Sanchez A; Risard S; Avery RL Ophthalmology; 2008 Oct; 115(10):e47-54. PubMed ID: 18708258 [TBL] [Abstract][Full Text] [Related]
6. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Brown DM; Campochiaro PA; Singh RP; Li Z; Gray S; Saroj N; Rundle AC; Rubio RG; Murahashi WY; Ophthalmology; 2010 Jun; 117(6):1124-1133.e1. PubMed ID: 20381871 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study. Kinge B; Stordahl PB; Forsaa V; Fossen K; Haugstad M; Helgesen OH; Seland J; Stene-Johansen I Am J Ophthalmol; 2010 Sep; 150(3):310-4. PubMed ID: 20591399 [TBL] [Abstract][Full Text] [Related]
8. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Spaide RF; Chang LK; Klancnik JM; Yannuzzi LA; Sorenson J; Slakter JS; Freund KB; Klein R Am J Ophthalmol; 2009 Feb; 147(2):298-306. PubMed ID: 18929354 [TBL] [Abstract][Full Text] [Related]
9. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Kaiser PK; Blodi BA; Shapiro H; Acharya NR; Ophthalmology; 2007 Oct; 114(10):1868-75. PubMed ID: 17628683 [TBL] [Abstract][Full Text] [Related]
10. The predictive value of optical coherence tomography after grid laser photocoagulation for diffuse diabetic macular oedema. Soliman W; Sander B; Soliman KA; Yehya S; Rahamn MS; Larsen M Acta Ophthalmol; 2008 May; 86(3):284-91. PubMed ID: 18005220 [TBL] [Abstract][Full Text] [Related]
11. Optical coherence tomographic pattern may predict visual outcome after intravitreal triamcinolone for diabetic macular edema. Gibran SK; Khan K; Jungkim S; Cleary PE Ophthalmology; 2007 May; 114(5):890-4. PubMed ID: 17467527 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of intravitreal triamcinolone acetonide in long standing diabetic macular edema: a microperimetry and optical coherence tomography study. Grenga P; Lupo S; Domanico D; Vingolo EM Retina; 2008 Oct; 28(9):1270-5. PubMed ID: 18664938 [TBL] [Abstract][Full Text] [Related]
13. Ranibizumab for refractory uveitis-related macular edema. Acharya NR; Hong KC; Lee SM Am J Ophthalmol; 2009 Aug; 148(2):303-309.e2. PubMed ID: 19427988 [TBL] [Abstract][Full Text] [Related]
14. Posterior hyaloid changes following intravitreal triamcinolone and macular laser for diffuse diabetic macular edema. Sivaprasad S; Ockrim Z; Massaoutis P; Ikeji F; Hykin PG; Gregor ZJ Retina; 2008; 28(10):1435-42. PubMed ID: 18628722 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial. Lam DS; Lai TY; Lee VY; Chan CK; Liu DT; Mohamed S; Li CL Retina; 2009 Mar; 29(3):292-9. PubMed ID: 19287286 [TBL] [Abstract][Full Text] [Related]
17. Relation between reduction of foveal thickness and visual acuity in diabetic macular edema treated with intravitreal triamcinolone. Larsson J; Zhu M; Sutter F; Gillies MC Am J Ophthalmol; 2005 May; 139(5):802-6. PubMed ID: 15860283 [TBL] [Abstract][Full Text] [Related]
18. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular oedema. Do DV; Nguyen QD; Shah SM; Browning DJ; Haller JA; Chu K; Yang K; Cedarbaum JM; Vitti RL; Ingerman A; Campochiaro PA Br J Ophthalmol; 2009 Feb; 93(2):144-9. PubMed ID: 19174400 [TBL] [Abstract][Full Text] [Related]
19. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Campochiaro PA; Brown DM; Awh CC; Lee SY; Gray S; Saroj N; Murahashi WY; Rubio RG Ophthalmology; 2011 Oct; 118(10):2041-9. PubMed ID: 21715011 [TBL] [Abstract][Full Text] [Related]
20. Anti-VEGF in treatment of diabetic macular edema. Boras I; Lazić R; Gabrić N; Lukić M; Dekaris I Coll Antropol; 2011 Sep; 35 Suppl 2():15-8. PubMed ID: 22220397 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]